Previous therapy with anthracyclines or taxanes for any malignancy If a patient has progressed in previous areas of primary disease that received definitive doses of radiation, these patients would require re-irradiation in previous high dose anatomic areas and are not eligible for this study. Patients with recurrent carcinoma of the vulva regardless of previous treatment Patient has had previous treatment with the study drug or other Wilms' tumor (WT)-related immune therapy Systemic treatment with interferon (IFN)-? within the previous months. Has received pegzilarginase as part of any previous therapy Previous treatment with venetoclax or other B-Cell Lymphoma (BCL-) inhibitor OR previous treatment with daratumumab or other anti-CD therapy. Any previous treatment with pevonedistat or other NEDD inhibitor Presence of any remaining toxicities due to previous chemotherapy Previous treatment with Apatinib. Recovery from significant toxicities from previous therapies and sufficient time since last dose of previous therapy Previous treatment with palbociclib Received previous therapy for malignancy within days History of previous chemotherapy Previous treatment with any prior BET inhibitor therapy Any previous autologous EBV specific T cell treatment. Patients who have had previous treatment with tivozanib are excluded Patients who have had previous treatment with nintedanib The disease should be progressing/relapsed during or after the previous treatment. Previous therapy with anthracyclines or taxanes for any malignancy. Chemotherapy treatment within the previous months Previous therapy with anthracyclines or taxanes for any malignancy Received previous non-cytotoxic, FDA-approved anticancer agent within previous weeks, or < half-lives since completion of previous therapy, whichever is shorter No previous treatment with the specific assigned study drug or any other drug sharing the same target Previous treatment with any HER-targeted therapy Erlotinib Previous treatment with vismodegib or any other hedgehog pathway inhibitor Previous hysterectomy and/or prior treatment for cervical precancer condition No previous regional treatment (includes surgery, radiation or liver-directed arterial or ablative therapy) Presence of active lymphoma or active PTLD, based on imaging performed within the previous months. Relapse or progression following previous autologous EBV specific T cell treatment. Patient must have had previous treatment with definitive surgery or radiation therapy or cryoablation relevant toxicity from previous treatment Have not recovered to ? Grade toxicity from previous anticancer treatments or previous IPs. No systemic treatment in the previous days. Patients with previous treatment with abraxane Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment. Previous intrapleural therapy for MPE on the same side Previous participation in a liposome bupivacaine study. No previous systemic treatment for cGVHD (including extracorporeal photopheresis [ECP]) Previous treatment with a pyrrolobenzodiazepine (PBD)-based drug Additional exclusion criteria for the SC- and ABBV- combination treatment regimen: Previous treatment with epacadostat, SD-, or any other IDO inhibitor or CpG molecule No previous HIPEC Previous serious adverse reactions to smallpox vaccination Hormonal manipulation (excluding -alpha-reductase inhibitors) that alters androgen production within the previous months; Patient has received any previous intravesical therapy for bladder cancer- chemotherapy, immunotherapy, or previous exposure to Qapzola in the last years Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment Previous radiotherapy in the pelvic region (eg, prostate) or previous rectal surgery (eg, total mesorectal excision [TME]) or any investigational treatment for rectal cancer Previous enrollment in this study, followed by withdrawal for any reason. Any previous local treatment of the prostate (i.e. radiation) A history of neurological complications due to past poliovirus (PV) infection would imply previous virus replication in the central nervous system (CNS); based on animal studies, previous exposure to poliovirus administered intracerebrally can reduce subsequent virus replication in the CNS COHORT (WITH SORFENIB): No previous systemic therapy including sorafenib or chemotherapy treatment; previous TACE and local treatments are permitted Patients may not have undergone previous treatment with lomustine. No previous cancer treatment with any cytotoxic agent for this malignancy At least weeks since any previous treatment for cancer Tumor recurrence after previous treatment, which must have included at least radiation therapy and one cytotoxic chemotherapy; there is no limit on number of previous recurrences or lines of treatment Previous treatment information (name of agent, treatment starting date, and date of progression) must be available for review Patients with a previous history of neurological complications due to polyoma virus (PV) infection Previous enrolment in this trial Previous treatment with talazoparib Patient with previous administration of immunosuppressive therapy for SAA Previous TSEB therapy with total dose > Gy Previous chemotherapy Gastrointestinal surgery within the previous months Previous treatment with AKT inhibitors (e.g., ARQ , MK-, GSK, AZD) Dose-volume histogram data and cross-sectional imaging from previous radiation must be obtained; electronic dosimetry records in Digital Imaging and Communications in Medicine (DICOM) format from previous radiation are strongly preferred Previous CNS surgery within weeks of treatment, with the exception of biopsy Patients who received previous anti-folate-containing chemotherapy History of a previous treated cancer except for the following: Previous serious adverse reactions to smallpox vaccination Patients must have relapsed after at least but at most prior lines of therapy, including rituximab-based immunochemotherapy and alkylating agents. A previous regimen is defined as one of the following: at least months of single-agent therapy; at least consecutive cyclesof polychemotherapy; autologous transplant; radioimmunotherapy. Previous exposure to other PIKi is acceptable provided there is no resistance. Previous therapy with antiandrogens within weeks Previous therapy with rabbit anti-thymocyte globulin (ATG); previous treatment with equine ATG is allowed if more than months ago \r\n* Note: previous myeloablative autologous transplant is permitted but not required Previous radiation therapy with anything other than standard radiation therapy (such as previous stereotactic radiosurgery) or previous treatment with an immune checkpoint inhibitor (i.e., nivolumab, pembrolizumab, ipilimumab) Previous history of haemoptysis (expectoration of more than . mL of blood), within three months prior to enrollment Previous treatment with farletuzumab or other folate receptor targeting agents No previous treatment with vandetanib; previous or ongoing treatment with metformin is allowed A \washout\ period of at least days from last previous cytotoxic chemotherapy will be required prior to starting treatment on this protocol; no washout period will be required for previous bcr-abl TKI therapy given with the aforementioned previous chemotherapy cycles; hydroxyurea and corticosteroids may be given as bridge therapy up until hours prior to initiating protocol treatment Previous treatment with AKT inhibitors (e.g., MK-, GSK, AZD) Previous radioimmunotherapy. Previous antibody-based therapy is allowed as long as ? days has elapsed from last dose to study treatment. Histologically or cytologically documented MDS of any risk group that has failed previous therapy (therapy failure is defined as patients who have been sufficiently treated with previous agents without response in the opinion of the treating physician, or whose disease has progressed or relapsed while on a hypomethylating agent) Previous biliary drainage by ERCP/PTC Previous chemotherapy for this tumor Has undergone ? previous regimens (depending on treatment arm) of cytoreductive therapies including, but not limited to, platinum-based compounds, taxanes, or -fluorouracil. for B, no prior systemic treatments should have been received for RM SCCHN Any previous BMT must have occurred at least months prior to start of conditioning Patients who have received < cycles of multiagent chemotherapy and patients who have received no multiagent chemotherapy within the months previous to umbilical cord blood transplant (UCBT) as well as patients experiencing graft failure following previous allogeneic transplant Patients who have received >= cycles of multiagent chemotherapy within the months previous to UCBT; patients who have had previous autologous transplant within months of UCBT are excluded regardless of history of recent treatment Patient has had previous treatment with poziotinib. Ongoing or previous anti-cancer treatment within weeks before randomization. Previous systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments); prior treatment for previous breast cancer or other neoplasms is allowed as long as it was completed at least year prior to inclusion into this trial. Patients must have the following minimum wash-out from previous treatments: Patients who tolerated previous administration with TMZ Previous treatment for NHL Previous discontinuation of treatment with deferiprone or deferoxamine due to adverse events; Previous or current treatment with mitotane or other antineoplastic drugs for ACC Previous radiation treatment in either breast at any time Previous treatment with CD-targeted therapy, with the exception of prior lisocabtagene maraleucel treatment in this protocol for subjects receiving retreatment Previous intravesical immunotherapy less than months before study entry; Note: if a patient is eligible for the study but has had intravesical immunotherapy within the past months, they can enroll in the study and initiation of treatment of the drug will be delayed until a minimum of days has passed since the previous treatment No more than calendar months from last dose of previous anti-EGFR mAb treatment to date of consent for this trial (regardless of the line of therapy in which it was used) Additional Exclusion Criteria for Subjects Assigned to Treatment B: Unacceptable AEs from previous bortezomib treatment; Ongoing Grade or higher peripheral neuropathy or neuropathic pain from previous bortezomib treatment; Intolerance or contraindications to anti-viral prophylaxis. Previous treatment with idelalisib at any time (ZYDELIG) History of prior breast cancer-specific therapy within the previous years (chemotherapy, radiation, anti-HER agents, endocrine agents, everolimus, CDK- inhibitors); previous unilateral radiation of the contralateral side in women scheduled for mastectomy is allowed; study gel will be applied to both breasts Treatment with corticosteroids other than physiological replacement within the previous week or treatment with immunosuppressive medication within the previous week. Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment BLADDER: The patient must be systemic treatment naive, previous intra-vesicle therapy is allowed Received chemotherapy drugs within previous weeks Previous retreatment with cetuximab following progression on initial course of cetuximab therapy Ongoing toxic manifestations of previous treatments. Previous therapy with pazopanib Any previous treatment with vosaroxin Individuals with a history of a previous malignancy are ineligible; also, exposure to previous anti-neoplastic treatment may alter the ability to tolerate or respond to the agents utilized in this protocol; exception: individuals with a previous malignancy treated with surgery only (no chemotherapy or radiotherapy) more than years prior to registration may be enrolled Previous sphincterotomy or bilio-enteric anastomosis Previous history of intravesical therapy allowed Previous treatment with eribulin mesylate Previous treatment with genetically engineered GD-CAR T cells; previous vaccine therapy, anti-GD mAb therapy or therapy with other genetically engineered T cells is not an exclusion criteria Patient who has received previous chemotherapy or radiation therapy in the previous months, except for empiric initial intrathecal administration at diagnosis; rituximab or steroid administration is not an exclusion criterion No previous chemotherapy Patient receiving an immunosuppressive treatment for GvHD treatment due to a previous allograft at the time of screening At least weeks since any previous treatment for cancer Previous chemotherapy for this tumor Previous chemotherapy or chemoradiotherapy outside of the InPACT trial Recovery from significant toxicities from previous therapies and sufficient time since last dose of previous therapy Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances Previous therapy with: Ongoing medically significant adverse events from previous treatment, regardless of the time period Previous cytotoxic, cytostatic, hormonal, biological or immunological treatment (ESA with or without G-CSF and iron chelating therapy and hydroxyurea are allowed under certain conditions, see exclusion criterion #) or biologic treatment for AML. Previous treatment with ibrutinib Patients who have had previous treatment with: Previous cancer treatment contraindicates this protocol therapy. No previous anti-cancer treatment The subject with a previous history of a non-invasive carcinoma is eligible if he/she has had successful curative treatment any time prior to Screening. Any medical contraindications or previous therapy that would preclude treatment with either IRX Regimen or or the surgery, reconstruction or adjuvant therapy required to treat the oral tumor appropriately Previous antiangiogenic treatment More than one previous treatment line with erlotinib, gefitinib or afatinib Participants must have never received previous R-CHOP treatment Previous therapy for metastatic gastroesophageal cancer; previous perioperative chemotherapy is allowed as long as the duration without treatment has been greater than months Previous systemic chemotherapy for MPM Previous treatment with SB- or ofatumumab Subject has had previous treatment with ART-. Less than months since the end of previous radiation Patients who have received systemic treatment with IFN-? within the previous months prior to enrolling into this study. Patients must have not received previous treatment with any of the study medications or similar drugs Has undergone a colectomy procedure in the previous two months Has an emergent infection related to a previous colectomy procedure Previous treatment with ibrutinib Have participated in a previous study of duvelisib, and: Have completed the required components of the previous study and be appropriate for enrollment into this long-term continued treatment and follow-up study, as determined by the Sponsor Previous serious adverse reactions to smallpox vaccination Previous treatment with any other compound that targets CD The subject with a previous history of a noninvasive carcinoma is eligible if in the opinion of the investigator he/she has had successful curative treatment any time prior to Screening and requires no further therapy for the malignancy. Previous treatment with any aminopeptidase inhibitor Subjects who have not recovered to Grade or toxicity from previous anti-cancer treatments or previous investigational agents. Previous failure of at least one fluoropyrimidine- and irinotecan-containing chemotherapy regimen for metastatic disease; Note: previous failure is defined as disease progression while receiving treatment or within weeks after the last dose of irinotecan; failure for this assessment is defined as any enlargement of measurable or assessable lesion(s) or the development of any new lesion; a rising tumor marker alone is not sufficient to define failure; patients can have received irinotecan in any previous line of therapy Patients who have had previous treatment with selinexor No more than previous treatments for cGVHD. Treatment nave or have failed on previous treatment for PRCC. Previous treatments may include: targeted therapy (i.e. sunitinib, sorafenib, bevacizumab, pazopanib, temsirolimus, and everolimus), traditional immunotherapy (i.e. interferon-a, Interleukin-), chemotherapy or a combination of chemoimmunotherapy. Ongoing toxic manifestations of previous treatments. Not have received bacillus Calmette-Gurin (BCG) or have completed previous BCG treatment > months prior to the baseline staging procedure. Previous laryngeal surgery Previous laser therapy within one year prior to protocol treatment Previous treatment with T-DM at any time; or previous treatment with any small molecule HER inhibitors including (but not limited to) lapatinib, neratinib, or afatinib within the last weeks prior to initiation of study therapy. Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances. No more than previous treatments for cGVHD, excluding topical agents. Has a previous treatment with irinotecan Subjects (other than those in the ibrutinib + JCAR combination therapy cohort) must have received previous treatment as follows: Participants who have received previous therapy with neratinib or fulvestrant Previous treatment with MLN and/or MLN; previous treatment with dual mTORC/ or dual PIK-mTOR inhibitors Previous serious adverse reactions to smallpox vaccination Previous adverse reactions to smallpox vaccination Previous assignment to treatment during this study Previous treatment with any HER-directed therapy, at any time, for any duration Previous therapy with a topoisomerase I or II inhibitor Patient who has had any prior radiotherapy to the treatment site(s); as in, definitive therapy for lesion of interest; field overlap from previous treatment is permitted at the discretion of the treating investigator Incomplete healing from previous oncologic or other major surgery Stable primary malignancy for previous months Previous treatment with cytotoxic chemotherapy, immunotherapy, radiotherapy or other lymphoma specific therapy within days before the screening visit or patient has not recovered from side effects of previous lymphoma-specific therapy. Participants who relapsed from their previous treatment(s) but were not refractory to any previous treatment. Previous treatment with isolated hepatic perfusion Previous treatment with agents that target the IGF receptor Previous treatment with dacarbazine (DTIC) or TMZ Any prior therapy for lymphoma within the previous weeks for standard treatments and within weeks for experimental therapies unless the patient has recovered from the nadir of the previous treatment to a level that meets the inclusion criteria Incomplete healing from previous oncologic or other major surgery Patients who have received treatment with IFN-? within the previous months prior to enrollment. Patients with HL who have received ASCT in the previous - days Previous irradiation for head and neck tumor; concurrent chemotherapy other than the treatment per protocol; previous chemotherapy =< months from start of radiation therapy (RT) Previous therapy directed against CD, such as MAbs or MAb conjugates No previous radiation, cytotoxic chemotherapy, radio surgery, or investigational treatment directed at the brain tumor at any time; no limit on number of previous surgical procedures of this tumor Previous treatment with definitive surgery or radiation therapy or both Patients who were receiving axitinib tablets at the time their previous trial ended Previous chemotherapy for any malignancy including temozolomide, dacarbazine (DTIC) or prior nitrosourea Patients on previous treatment with carboplatin. Patients who have received previous chemotherapy for the treatment of metastatic or unresectable gastric or GEJ adenocarcinoma are ineligible; patients who have received previous pre- or post-operative chemotherapy or chemoradiation are ineligible if therapy was completed less than months prior to study registration; patients must have recovered from adverse events from any previous therapy Previous ZD treatment Patients who have had previous treatment with topotecan Residual AEs >Grade from previous treatment Residual AE from previous treatment > Grade Previous treatment with sunitinib. Have had a previous extra pleural pneumonectomy (EPP). Metastatic disease that has progressed on previous therapy or previous therapy was not tolerated Previous radiation treatment to the tumor Received thrombolytic agents w/in the previous month Residual relevant toxicity resulting from previous therapy Have had previous transplants and/or prior mobilization attempts Previous immune-mediated therapy Patients should be without any persisting clinically significant > grade hematological/non hematological toxicities from previous treatments that would preclude evaluation of toxic effects of study treatment; grade residual toxicity will be acceptable; patients should be off previous treatment at least weeks from prior therapies before treatment start Incomplete healing from previous oncologic treatments or other major surgery Have received previous treatment with ramucirumab or LY, except for participants enrolled in cohort B (Gastric or GEJ adenocarcinoma) and B (non- small cell lung cancer) who may have received previous ramucirumab treatment. Previous use of mitoxantrone and etoposide combination therapy within the preceding days of screening Previous cardiac operation. No previous treatment with chemotherapy for AML, other than hydroxyurea; previous treatment with hypomethylating agents is acceptable Previous treatment defined as follows:\r\n* Previous participation in this study\r\n* Previous radiotherapy to the site of vertebroplasty prior to study enrollment\r\n* Samarium therapy at any previous time Previous treatment with agents targeting the insulin like growth factor (IGF) signalling pathway. Previous treatment with nintedanib Chemotherapy treatment within the previous months. Have an interval from previous neurotoxic platinums of less than months and/or from previous other neurotoxic drugs less than months (e.g, taxanes) unless reasonably recovered from all grades of neurotoxicity as judged by the investigator Previous systemic therapy to treat small-cell lung cancer (SCLC). Subjects with recurrent or progressive limited-stage SCLC after previous systemic treatment are not eligible for study participation. More than one previous episode of CDAD in the -month period prior to randomization. Have not recovered to ? Grade toxicity from previous anticancer treatments or previous investigational agents Evidence of residual disease either by increased blasts count (> %) or persistence of previous known cytogenetics abnormalities Previous treatment with vemurafenib Concurrent or previous treatment with inhibitors of DLL Previous treatment with fulvestrant Previous treatment with AKT inhibitors Unmanageable toxicity, an adverse event, progression of disease, or withdrawal of consent as reason for discontinuing treatment from previous sponsor-initiated siltuximab study Had previous open thoracotomy procedures > weeks since discontinuation of tivozanib treatment on a previous protocol Any previous BMT must have occurred at least months prior to start of conditioning No previous allogeneic BMT (syngeneic BMT permissible) Previous treatment with ofatumumab. Previous chemo within wks Previous chemo within wks Previous treatment with ofatumumab. For phase I, any solid tumors, including lymphoma, that progressed or were stable as best response on at least one previous therapy but no more than two previous cytotoxic therapies and are evaluable Incomplete healing from previous surgery. The subject has a treatment related serious adverse event that remains unresolved or unstable or had pazopanib permanently stopped in a previous study because of intolerate or because it was unsuccessful in treating your cancer Relative contraindications: presence of bleeding disorders; distortion of anatomy due to local injury or deformity; previous long-term venous catheterization; history of vasculitis; previous injection of sclerosis agents; previous radiation therapy Previous treatment with lenvatinib mesylate (E) Previous treatment with tocilizumab (TCZ) Patients who have had previous treatment with pazopanib or topotecan Previous treatment with all of the following: lapatinib, and trastuzumab emtansine; (patients are eligible if treated with or less of these agents) Have smoked daily or nearly every day in the previous months up to the date of surgical consult AND have smoked at least one puff in the previous days Previous radiation in the operated breast Any previous treatment for vulvar HSIL within weeks prior to screening; Previous cancer genetic testing or counseling, or prior germline multigene panel testing Received previous chemotherapy Patients who have received previous treatment with ionizing radiation Participated in a previous elotuzumab protocol (including, but not limited to HuLuc-, CA, CA, or CA) and is deemed by the investigator to be deriving benefit from elotuzumab and/or other study drugs as defined by the previous protocol Surgical treatment in the previous month Previous or ongoing physical therapy treatments are acceptable Previous neurosurgery on the brain Previous scar or mesh at the level of ileal conduit Participated during a previous admission Previous treatment with low level laser (regardless of indication) Previous participation in GCRA PATIENT: Informed of diagnosis of incurable disease within the previous weeks Previous antiangiogenic therapy Previous, preoperative celiac nerve block History of Guillain-Barre within weeks of previous influenza vaccination Known previous treatment failure to erythropoiesis stimulating agents (ESAs) (eg, rHuEPO, darbepoetin alfa). Previous intrapleural therapy for MPE on the same side Individuals with previous radiation treatments to the breast or axilla areas Previous laser treatment of telangiectasias Previous therapy with cetuximab within months of consent Previous treatment with topical menthol (menthol/methylsalicylate products like BenGay, Aspercreme, or Icy Hot) of any concentration within the previous month Previous cisplatin treatment Previous genetic testing or counseling regarding cancer risk Subjects with a previous esophagectomy Previous radiation to both breasts Any previous treatment for HCV =< months prior to registration Previous or current treatment with GLP- receptor agonists (e.g. exenatide, liraglutide). Enrolment in a previous study with netupitant (either alone or in combination with palonosetron). Received a negative mammography screening result in the previous four weeks Have had antibiotic therapy, probiotic supplements, or professional cleaning within the previous months Any adenoma that was not completely removed during previous colonoscopy Previous adverse reactions to smallpox vaccination History of prior breast cancer-specific therapy within the previous years; previous unilateral radiation in women scheduled for mastectomy of the contralateral side is allowed Previous ablative therapy for Barretts esophagus Have changed type of hormonal contraception during the previous weeks Use of tamoxifen, raloxifene, or chemotherapy within the previous months Previous treatment wth any TERT or IL- containing therapy, or any other DNA immunotherapy; Ongoing medically significant adverse events from previous treatment, regardless of the time period Patient has not received any previous brain RT. Previous partial of total colectomy Prior treatment with alpha radiation therapy (Radium Ra chloride; Xofigo) during the previous days History of previous administration of GBCA Previous radiation to the breast or axilla Locoregional treatment of hepatocellular carcinoma within the prior months or chemotherapy within the previous months Previous systemic or radiation treatment for cancer of any type within year Previous treatment with radiation or surgery to a significant percentage of bony metastatic sites Previous anaphylactic reaction to either FDHT or FDG History of taken antibiotics in the previous months Previous hypersensitivity reaction to LAR octreotide Previous prostrate surgeries Previous systemic or radiation treatment for another cancer of any type within the last months Previous treatment with CDX- or other anti-ErbB targeted agents. Cohort only: prior treatment with previous VEGFR active multikinase inhibitor Has received previous treatment with another agent targeting the T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (TIGIT) receptor Has had previous surgery or radiation to node basins that would be involved in the ILM procedure Prior treatment with alpha radiation therapy (Radium Ra chloride; Xofigo) during the previous days Patient must not have a previous history of laryngeal cancer Bronchoscopy or any other lung procedure for any reason within the previous year Previous treatment with BCR-ABL inhibitors other than nilotinib for more than a total cumulative duration of weeks Previous treatment with alpha-interferon of any duration Patients must have completed all previous anticancer therapy for at least weeks prior to the first planned dose of omacetaxine, except as noted below, and must have fully recovered from side effects of a previous therapy. At least weeks since any previous treatment for cancer Have not recovered to ? Grade toxicity from previous anticancer treatments or previous investigational products (IPs) Previous treatment with poziotinib prior to study participation.